BPC-157 vs. Tesamorelin: approval status matters
Summary
Both are peptides discussed in recovery and body-composition contexts, but their regulatory footing is very different. Tesamorelin is FDA-approved for a specific condition; BPC-157 is not FDA-approved for any use and lacks human trials.
At a glance
| Dimension | BPC-157 | Tesamorelin |
|---|---|---|
| FDA approval | Not FDA-approved | FDA-approved (HIV-associated lipodystrophy) |
| Human evidence | Essentially none (animal studies) | Randomized trials in its approved population |
| Evidence level | Preclinical | Established (for approved use) |
BPC-157
- FDA approval
- Not FDA-approved
- Human evidence
- Essentially none (animal studies)
- Evidence level
- Preclinical
Tesamorelin
- FDA approval
- FDA-approved (HIV-associated lipodystrophy)
- Human evidence
- Randomized trials in its approved population
- Evidence level
- Established (for approved use)
What they have in common
- Both are peptides sometimes marketed for body composition or recovery.
- Both warrant caution around growth/angiogenic effects and cancer history.
Material differences
- Tesamorelin is FDA-approved and studied in humans for a defined indication; BPC-157 is neither.
- BPC-157 products are unregulated with unverified contents.
Decision considerations
- Whether a treatment is FDA-approved for your specific situation.
- The near-total absence of human data for BPC-157.
- Legality and product quality of unapproved peptides.
Sources
- 1.EGRIFTA (tesamorelin for injection) — Prescribing Information — U.S. Food and Drug Administration. Government agencyAccessed July 24, 2026.
- 2.Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks — U.S. Food and Drug Administration. Government agencyAccessed July 24, 2026.
- 3.Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act — U.S. Food and Drug Administration. Government agencyAccessed July 24, 2026.
Last reviewed (yesterday)